Lv3
216 积分 2025-03-06 加入
Differential Binding of Sarilumab and Tocilizumab to IL‐6Rα and Effects of Receptor Occupancy on Clinical Parameters
1个月前
已完结
Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis
1个月前
已完结
Tocilizumab in patients with adult-onset still's disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial
2个月前
已完结
Bispecific T-cell engagers in autoimmune diseases: mechanisms of action, clinical evidence challenges, and therapeutic perspectives
5个月前
已完结
Chimeric antigen receptor-based cellular therapy in autoimmune diseases: A systematic review and meta-analysis of clinical, serological and safety outcomes
5个月前
已完结
Nerandomilast in Patients with Progressive Pulmonary Fibrosis
5个月前
已完结
Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial
11个月前
已完结
Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial
11个月前
已完结
Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis–Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial
11个月前
已完结
OP0295 RITUXIMAB VERSUS TOCILIZUMAB IN PATIENTS WITH SYSTEMIC SCLEROSIS: 52-WEEK OUTCOMES OF A STRATIFIED BIOPSY-DRIVEN, OPEN-LABEL, RANDOMIZED CONTROLLED TRIAL
11个月前
已完结